Trial Profile
A study evaluating prognostic ability of cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumours.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 02 Dec 2016 New trial record
- 11 Oct 2016 Results assessing prognostic role of CD and DI of everolimus for patients with pancreatic neuroendocrine tumours presented at the 41st European Society for Medical Oncology Congress